PEStore

Venture Capital

Decheng Capital

Decheng Capital backs early-stage and high-growth companies, typically pre-profit, from United States. It states a focus on healthcare & life sciences.

Capital raised$624macross 6 SEC-filed vehicles
Most recent fund2024filing since 2015
HeadquartersUnited States
Stated fund size$2.5B+ AUM

Stated investment criteria

What Decheng Capital says it buys

Read from Decheng Capital’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.

Founded20122
People listed on its team page31

A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Decheng Capital to consider any particular business, and nothing on this page is represented as being for sale.

SEC filings

What Decheng Capital has raised

From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.

Vehicles filed6
Total capital raised$624m
Largest single vehicle$452m
Filing history2015 to 2024
Smallest accepted commitment$5m
Filed fromCAYMAN ISLANDS

Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.

Regulatory record

How Decheng Capital is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusSEC registered
Regulatory assets under management$2.7bn
Employees23
Private funds advised8 · $2.7bn gross
SEC adviser numberCRD 293073

Portfolio

Disclosed holdings

Companies Decheng Capital lists on its own website. 5 carry a stated investment year.

CompanyInvestedYears heldRecorded transaction
Cellares20233
Prometheus Biosciences20233
Upstream Bio20233
Aardvark Therapeutics20242
Mammoth Biosciences20242
3SBio
ACELYRIN
AK Medical
Aadi
Accuragen
Adaptive Biotechnologies
Adela
Albireo Pharma
Alpine Immune Sciences
AnHeart Therapeutics
Arcus Biosciences
Ark Biosciences
BCFoods
BeyondSpring Pharmaceuticals
Bioheng
CG Oncology
Centricity Vision
ConjugateBio
Cue Health
Encodia
EpimAb Biotherapeutics
Equillium Bio
Everest Medicines
Firefly Biologics
GRAIL
GRIT Biotechnology
Harton Therapeutics
Hummingbird Bioscience
IMPACT Therapeutics
ImmPACT Bio
Insight Lifetech
Invitae
KeChow Pharma
Kind Pharmaceuticals
LYNK Pharmaceuticals
LevitasBio
Medical Creations
Mirvie
Nalu Medical
Omniome
PackGene Biotech
Polares Medical
SINO Medical Sciences Technology
Scynexis
Shanghai Legend Medical
Take2
Terns Pharmaceutical
USCI Medical Laboratory
VintaBio
Watchmaker Genomics
Zentalis

Compiled from Decheng Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this Decheng Capital?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other venture capital investors active in healthcare & life sciences.